To The Moon

Summary Johnson & Johnson might be the worst performing big pharma stock YTD, but there's upside possible for it in the remainder of 2024. Revenue growth guidance was upgraded and even with a downgrade in EPS guidance, the number is still expected to see a YoY increase. Its market multiples indicate the possibility of some uptick, and there are dividends to consider too. JNJ isn't without its risk, due to Stelara's patent expirations and litigation against it, but for now, it's a safer stock than not. yuelan Among the big five pharmaceutical stocks by market capitalisation, Johnson & Johnson (NYSE:JNJ) has been the worst performer year-to-date [YTD]. While the rest of them have all seen at least some uptick, it’s actually down

Summary Rio Tinto's share price remains firmly underwhelming as iron ore prices have weakened and its prospects aren't encouraging either. While some support is possible from aluminium and copper, the company's upcoming H1 2024 results can show weakness. The trend can also continue for the full year 2024. While Rio Tinto's forward dividend yield is notable, the market multiples don't indicate price upside, making it one only for long-term dividend investors and not for capital appreciation right now. temizyurek Since I last wrote about the Australian iron ore miner Rio Tinto (NYSE:RIO) in March, its share price is up by

Summary Merck's price rise might have stalled in the past quarter, but at least for now, there's potential for some upswing again. Keytruda continues to drive revenue growth, and expansion in its usage along with positive news on other treatments and an acquisition related bump up too, the sales outlook is healthy. Concerns arise, however, regarding the earnings outlook due to the acquisition of Eyebiotech, which can impact non-GAAP EPS and potentially reduce guidance. So far, the acquisition costs aren't enough to materially affect the forward P/E relative to the stock's five-year average, though. JHVEPhoto/iStock Editorial via Getty Images Since I last wrote about the pharmaceuticals stock Merck & Co., Inc. (NYSE:MRK) in April,

Summary Considering the Fed's close watch on labor market figures, the May figures will be key as they may well confirm that a slowdown is indeed underway. After a weak April, the employment situation is forecast to be sluggish again. This ties in with muted economic trends seen in GDP, corporate profits and even other labor surveys. Along with the likely start of a rate cut cycle for other central banks, this can pull the Fed's rate cuts forward too. A weaker economy and lower interest rates suggest plenty of ideas on what to buy and what not to right now. For the short term, the broad indexes look avoidable, while geopolitically driven stocks are worth considering. shapecharge From a purely analytical perspective, the unfolding of macroeconomic trends in the US economy has been fa

Summary Tesla, Inc. share price weakness YTD can continue into the remainder of the year, going by its increasing challenges. The company's labor challenges drag on, while demand weakness and higher operating expenses have squeezed the operating profit margin. The stock's market multiples also remain high compared to peers, even as it loses market share in its big U.S. market and despite the price decline. While there are some positives, like some easing of inflation in Sweden and Germany, the possibility of production normalizing and stabilization in profits as Tesla undertakes cost-cutting, it's not enough to make a case for the stock for 2024. JasonDoiy In the past six months of tracking the Tesla, Inc. (NASDAQ:TSLA) stock here o

Summary In a slowing luxury market, Prada stands out for its double-digit revenue growth and rising net margins. It's little wonder then that it's trading at a premium compared to other luxury stocks, and there can be justification for an even higher premium. If it maintains its current performance, the stock has good prospects for the rest of 2024 and its ability to grow in challenging times also makes it a long-term buy. resulmuslu/iStock Editorial via Getty Images Since the last time I wrote about the luxury fashion stock Prada (OTCPK:PRDSF) (OTCPK:PRDSY) in

Summary In line with the recent luxury rally, Richemont's stock price has increased by 32.5% since November 2023, despite warnings of slowing sales in Europe. To be fair, some improvement has been seen in sales growth in Q3 FY24, supported by China's recovery and a surprising spurt in the Americas' demand. But with the macro outlook somewhat concerning, the recent improvement can't be taken for granted. And the stock's now elevated market multiples don't help either. Frazer Harrison Since the last time I wrote about the Swiss luxury company and Cartier owner Compagnie Financière Richemont (OTCPK:CFRUY) (

Summary Much has changed for the miner Rio Tinto's stock in the past quarter, making it attractive again. It saw a significant earnings uptick in H2 2023 on improved iron ore prices and with forecasts for the commodity looking good, better times can be expected in 2024. Even after a dividend cut, the dividend yield looks good too, and a price correction has contributed to more competitive market multiples. A soft global economy can impact commodity demand, which in turn could affect Rio Tinto, but no alarm bells are going off to this extent right now. temizyurek An analysis of the iron ore miner Rio Tinto (NYSE:RIO) is a very good example right now of just how much things can change in just a quarter to alter perspective on it. When

Summary BP has underperformed in the past year, but a 6.6% price jump on its recent results indicates that the tide can turn in 2024. With a comfortable dividend payout ratio and the potential for an earnings upside this year, dividends can continue to grow while increased share buybacks can also bump up the price. While its slow transition to cleaner energy is a long-term concern, going by BP's forecasts, for now, the stock looks good based on possible returns to investors and market multiples. Matt Cardy/Getty Images News Compared to its UK-based peer Shell plc (SHEL), the oil and gas stock BP p.l.c. (NYSE:BP) has underperformed in the past year. Not only has its price declined by 13%

Summary Rentokil Initial's stock has declined by 7.8% in 2023, The company's latest trading update has disappointed investors, with warnings of weakness in its North American market. However, Rentokil Initial's revenues are still rising at a healthy rate, and it expects company-wide adjusted operating margins to meet expectations for 2023. But its market multiples don't make a strong case for a short-term buy, which couples with downside performance risks. From a long-term perspective though, the company is still doing just fine. Ivan-balvan The UK based pest control and hygiene services provider Rentokil Initial (NYSE:RTO) has had a somewhat weak year in the stock market so far in 2023, with a price decline of 7.8% Even considering di